Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64


The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib.

Marzi L, Szabova L, Gordon M, Weaver Ohler Z, Sharan SK, Beshiri ML, Etemadi M, Murai J, Kelly K, Pommier Y.

Clin Cancer Res. 2019 Oct 15;25(20):6206-6216. doi: 10.1158/1078-0432.CCR-19-0419. Epub 2019 Aug 13.


microRNA-155 positively regulates glucose metabolism via PIK3R1-FOXO3a-cMYC axis in breast cancer.

Kim S, Lee E, Jung J, Lee JW, Kim HJ, Kim J, Yoo HJ, Lee HJ, Chae SY, Jeon SM, Son BH, Gong G, Sharan SK, Chang S.

Oncogene. 2018 May;37(22):2982-2991. doi: 10.1038/s41388-018-0124-4. Epub 2018 Mar 12.


Clinical testing of BRCA1 and BRCA2: a worldwide snapshot of technological practices.

Toland AE, Forman A, Couch FJ, Culver JO, Eccles DM, Foulkes WD, Hogervorst FBL, Houdayer C, Levy-Lahad E, Monteiro AN, Neuhausen SL, Plon SE, Sharan SK, Spurdle AB, Szabo C, Brody LC; BIC Steering Committee.

NPJ Genom Med. 2018 Feb 15;3:7. doi: 10.1038/s41525-018-0046-7. eCollection 2018.


BRE/BRCC45 regulates CDC25A stability by recruiting USP7 in response to DNA damage.

Biswas K, Philip S, Yadav A, Martin BK, Burkett S, Singh V, Babbar A, North SL, Chang S, Sharan SK.

Nat Commun. 2018 Feb 7;9(1):537. doi: 10.1038/s41467-018-03020-6.


Intragenic DNA methylation and BORIS-mediated cancer-specific splicing contribute to the Warburg effect.

Singh S, Narayanan SP, Biswas K, Gupta A, Ahuja N, Yadav S, Panday RK, Samaiya A, Sharan SK, Shukla S.

Proc Natl Acad Sci U S A. 2017 Oct 24;114(43):11440-11445. doi: 10.1073/pnas.1708447114. Epub 2017 Oct 9.


Survival of BRCA2-Deficient Cells Is Promoted by GIPC3, a Novel Genetic Interactor of BRCA2.

Ding X, Philip S, Martin BK, Pang Y, Burkett S, Swing DA, Pamala C, Ritt DA, Zhou M, Morrison DK, Ji X, Sharan SK.

Genetics. 2017 Dec;207(4):1335-1345. doi: 10.1534/genetics.117.300357. Epub 2017 Oct 11.


RADX Promotes Genome Stability and Modulates Chemosensitivity by Regulating RAD51 at Replication Forks.

Dungrawala H, Bhat KP, Le Meur R, Chazin WJ, Ding X, Sharan SK, Wessel SR, Sathe AA, Zhao R, Cortez D.

Mol Cell. 2017 Aug 3;67(3):374-386.e5. doi: 10.1016/j.molcel.2017.06.023. Epub 2017 Jul 20.


Acquired cross-linker resistance associated with a novel spliced BRCA2 protein variant for molecular phenotyping of BRCA2 disruption.

Meyer S, Stevens A, Paredes R, Schneider M, Walker MJ, Williamson AJK, Gonzalez-Sanchez MB, Smetsers S, Dalal V, Teng HY, White DJ, Taylor S, Muter J, Pierce A, de Leonibus C, Rockx DAP, Rooimans MA, Spooncer E, Stauffer S, Biswas K, Godthelp B, Dorsman J, Clayton PE, Sharan SK, Whetton AD.

Cell Death Dis. 2017 Jun 15;8(6):e2875. doi: 10.1038/cddis.2017.264.


Synthetic lethality vs. synthetic viability due to PARP1 and BRCA2 loss.

Ding X, Sharan SK.

Transl Cancer Res. 2017 Mar;6(Suppl 2):S441-S442. doi: 10.21037/tcr.2017.03.42. No abstract available.


Erratum: Replication fork stability confers chemoresistance in BRCA-deficient cells.

Chaudhuri AR, Callen E, Ding X, Gogola E, Duarte AA, Lee JE, Wong N, Lafarga V, Calvo JA, Panzarino NJ, John S, Day A, Crespo AV, Shen B, Starnes LM, de Ruiter JR, Daniel JA, Konstantinopoulos PA, Cortez D, Cantor SB, Fernandez-Capetillo O, Ge K, Jonkers J, Rottenberg S, Sharan SK, Nussenzweig A.

Nature. 2016 Nov 17;539(7629):456. doi: 10.1038/nature19826. Epub 2016 Sep 28. No abstract available.


Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies.

Ding X, Ray Chaudhuri A, Callen E, Pang Y, Biswas K, Klarmann KD, Martin BK, Burkett S, Cleveland L, Stauffer S, Sullivan T, Dewan A, Marks H, Tubbs AT, Wong N, Buehler E, Akagi K, Martin SE, Keller JR, Nussenzweig A, Sharan SK.

Nat Commun. 2016 Aug 8;7:12425. doi: 10.1038/ncomms12425.


Interaction with PALB2 Is Essential for Maintenance of Genomic Integrity by BRCA2.

Hartford SA, Chittela R, Ding X, Vyas A, Martin B, Burkett S, Haines DC, Southon E, Tessarollo L, Sharan SK.

PLoS Genet. 2016 Aug 4;12(8):e1006236. doi: 10.1371/journal.pgen.1006236. eCollection 2016 Aug.


Replication fork stability confers chemoresistance in BRCA-deficient cells.

Ray Chaudhuri A, Callen E, Ding X, Gogola E, Duarte AA, Lee JE, Wong N, Lafarga V, Calvo JA, Panzarino NJ, John S, Day A, Crespo AV, Shen B, Starnes LM, de Ruiter JR, Daniel JA, Konstantinopoulos PA, Cortez D, Cantor SB, Fernandez-Capetillo O, Ge K, Jonkers J, Rottenberg S, Sharan SK, Nussenzweig A.

Nature. 2016 Jul 21;535(7612):382-7. doi: 10.1038/nature18325. Erratum in: Nature. 2016 Nov 17;539(7629):456.


BRCA2 minor transcript lacking exons 4-7 supports viability in mice and may account for survival of humans with a pathogenic biallelic mutation.

Thirthagiri E, Klarmann KD, Shukla AK, Southon E, Biswas K, Martin BK, North SL, Magidson V, Burkett S, Haines DC, Noer K, Matthai R, Tessarollo L, Loncarek J, Keller JR, Sharan SK.

Hum Mol Genet. 2016 May 15;25(10):1934-1945. Epub 2016 Feb 26.


Loss of oncogenic miR-155 in tumor cells promotes tumor growth by enhancing C/EBP-β-mediated MDSC infiltration.

Kim S, Song JH, Kim S, Qu P, Martin BK, Sehareen WS, Haines DC, Lin PC, Sharan SK, Chang S.

Oncotarget. 2016 Mar 8;7(10):11094-112. doi: 10.18632/oncotarget.7150.


Cripto-1 as a novel therapeutic target for triple negative breast cancer.

Castro NP, Fedorova-Abrams ND, Merchant AS, Rangel MC, Nagaoka T, Karasawa H, Klauzinska M, Hewitt SM, Biswas K, Sharan SK, Salomon DS.

Oncotarget. 2015 May 20;6(14):11910-29.


BRCA1 Circos: a visualisation resource for functional analysis of missense variants.

Jhuraney A, Velkova A, Johnson RC, Kessing B, Carvalho RS, Whiley P, Spurdle AB, Vreeswijk MP, Caputo SM, Millot GA, Vega A, Coquelle N, Galli A, Eccles D, Blok MJ, Pal T, van der Luijt RB, Santamariña Pena M, Neuhausen SL, Donenberg T, Machackova E, Thomas S, Vallée M, Couch FJ, Tavtigian SV, Glover JN, Carvalho MA, Brody LC, Sharan SK, Monteiro AN; Evidence-based Network for the Interpretation of Germline Mutant Alleles Consortium.

J Med Genet. 2015 Apr;52(4):224-30. doi: 10.1136/jmedgenet-2014-102766. Epub 2015 Feb 2.


An efficient pipeline for the generation and functional analysis of human BRCA2 variants of uncertain significance.

Hendriks G, Morolli B, Calléja FM, Plomp A, Mesman RL, Meijers M, Sharan SK, Vreeswijk MP, Vrieling H.

Hum Mutat. 2014 Nov;35(11):1382-91. doi: 10.1002/humu.22678. Epub 2014 Sep 11.


A novel splice site mutation in the noncoding region of BRCA2: implications for Fanconi anemia and familial breast cancer diagnostics.

Bakker JL, Thirthagiri E, van Mil SE, Adank MA, Ikeda H, Verheul HM, Meijers-Heijboer H, de Winter JP, Sharan SK, Waisfisz Q.

Hum Mutat. 2014 Apr;35(4):442-6. doi: 10.1002/humu.22505. Epub 2014 Feb 15.


MMTV-Espl1 transgenic mice develop aneuploid, estrogen receptor alpha (ERα)-positive mammary adenocarcinomas.

Mukherjee M, Ge G, Zhang N, Edwards DG, Sumazin P, Sharan SK, Rao PH, Medina D, Pati D.

Oncogene. 2014 Nov 27;33(48):5511-5522. doi: 10.1038/onc.2013.493. Epub 2013 Nov 25.


Manipulating the Mouse Genome Using Recombineering.

Biswas K, Sharan SK.

Adv Genet Eng. 2013;2(2). pii: 108. doi: 10.4172/2169-0111.1000108. Epub 2013 Jun 27.


The role of epigenetic transcriptional regulation in BRCA1-mediated tumor suppression.

Chang S, Sharan SK.

Transcription. 2013 Jan-Feb;4(1):24-8. doi: 10.4161/trns.22600. Epub 2012 Nov 6. Review.


BRCA1 and microRNAs: emerging networks and potential therapeutic targets.

Chang S, Sharan SK.

Mol Cells. 2012 Nov;34(5):425-32. doi: 10.1007/s10059-012-0118-y. Epub 2012 Jul 24. Review.


Functional evaluation of BRCA2 variants mapping to the PALB2-binding and C-terminal DNA-binding domains using a mouse ES cell-based assay.

Biswas K, Das R, Eggington JM, Qiao H, North SL, Stauffer S, Burkett SS, Martin BK, Southon E, Sizemore SC, Pruss D, Bowles KR, Roa BB, Hunter N, Tessarollo L, Wenstrup RJ, Byrd RA, Sharan SK.

Hum Mol Genet. 2012 Sep 15;21(18):3993-4006. doi: 10.1093/hmg/dds222. Epub 2012 Jun 7.


Epigenetic control of an oncogenic microRNA, miR-155, by BRCA1.

Chang S, Sharan SK.

Oncotarget. 2012 Jan;3(1):5-6. Epub 2012 Jan 25. No abstract available.


Using recombineering to generate point mutations:galK-based positive-negative selection method.

Biswas K, Stauffer S, Sharan SK.

Methods Mol Biol. 2012;852:121-31. doi: 10.1007/978-1-61779-564-0_10.


Using recombineering to generate point mutations: the oligonucleotide-based "hit and fix" method.

Chang S, Stauffer S, Sharan SK.

Methods Mol Biol. 2012;852:111-20. doi: 10.1007/978-1-61779-564-0_9.


Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155.

Chang S, Wang RH, Akagi K, Kim KA, Martin BK, Cavallone L; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Haines DC, Basik M, Mai P, Poggi E, Isaacs C, Looi LM, Mun KS, Greene MH, Byers SW, Teo SH, Deng CX, Sharan SK.

Nat Med. 2011 Sep 25;17(10):1275-82. doi: 10.1038/nm.2459. Erratum in: Nat Med. 2011 Nov;17(11):1521. Nat Med. 2011 Oct;17(10):2 p following 1282.


A comprehensive functional characterization of BRCA2 variants associated with Fanconi anemia using mouse ES cell-based assay.

Biswas K, Das R, Alter BP, Kuznetsov SG, Stauffer S, North SL, Burkett S, Brody LC, Meyer S, Byrd RA, Sharan SK.

Blood. 2011 Sep 1;118(9):2430-42. doi: 10.1182/blood-2010-12-324541. Epub 2011 Jun 30.


Targeted JAM-C deletion in germ cells by Spo11-controlled Cre recombinase.

Pellegrini M, Claps G, Orlova VV, Barrios F, Dolci S, Geremia R, Rossi P, Rossi G, Arnold B, Chavakis T, Feigenbaum L, Sharan SK, Nussenzweig A.

J Cell Sci. 2011 Jan 1;124(Pt 1):91-9. doi: 10.1242/jcs.072959. Epub 2010 Dec 8.


Functional analysis of human BRCA2 variants using a mouse embryonic stem cell-based assay.

Kuznetsov SG, Chang S, Sharan SK.

Methods Mol Biol. 2010;653:259-80. doi: 10.1007/978-1-60761-759-4_16. Review.


Functional redundancy of exon 12 of BRCA2 revealed by a comprehensive analysis of the c.6853A>G (p.I2285V) variant.

Li L, Biswas K, Habib LA, Kuznetsov SG, Hamel N, Kirchhoff T, Wong N, Armel S, Chong G, Narod SA, Claes K, Offit K, Robson ME, Stauffer S, Sharan SK, Foulkes WD.

Hum Mutat. 2009 Nov;30(11):1543-50. doi: 10.1002/humu.21101.


Expression of human BRCA1 variants in mouse ES cells allows functional analysis of BRCA1 mutations.

Chang S, Biswas K, Martin BK, Stauffer S, Sharan SK.

J Clin Invest. 2009 Oct;119(10):3160-71. doi: 10.1172/JCI39836. Epub 2009 Sep 21.


Recombineering: a homologous recombination-based method of genetic engineering.

Sharan SK, Thomason LC, Kuznetsov SG, Court DL.

Nat Protoc. 2009;4(2):206-23. doi: 10.1038/nprot.2008.227.


Loss of Rad51c leads to embryonic lethality and modulation of Trp53-dependent tumorigenesis in mice.

Kuznetsov SG, Haines DC, Martin BK, Sharan SK.

Cancer Res. 2009 Feb 1;69(3):863-72. doi: 10.1158/0008-5472.CAN-08-3057. Epub 2009 Jan 20.


A handcuff model for the cohesin complex.

Zhang N, Kuznetsov SG, Sharan SK, Li K, Rao PH, Pati D.

J Cell Biol. 2008 Dec 15;183(6):1019-31. doi: 10.1083/jcb.200801157.


Degradation of BRCA2 in alkyltransferase-mediated DNA repair and its clinical implications.

Philip S, Swaminathan S, Kuznetsov SG, Kanugula S, Biswas K, Chang S, Loktionova NA, Haines DC, Kaldis P, Pegg AE, Sharan SK.

Cancer Res. 2008 Dec 1;68(23):9973-81. doi: 10.1158/0008-5472.CAN-08-1179.


Mouse embryonic stem cell-based functional assay to evaluate mutations in BRCA2.

Kuznetsov SG, Liu P, Sharan SK.

Nat Med. 2008 Aug;14(8):875-81. doi: 10.1038/nm.1719. Epub 2008 Jul 6.


Model systems for studying skeletal dysplasias caused by TSP-5/COMP mutations.

Posey KL, Yang Y, Veerisetty AC, Sharan SK, Hecht JT.

Cell Mol Life Sci. 2008 Mar;65(5):687-99. doi: 10.1007/s00018-007-7485-0. Review.


RAD51C deficiency in mice results in early prophase I arrest in males and sister chromatid separation at metaphase II in females.

Kuznetsov S, Pellegrini M, Shuda K, Fernandez-Capetillo O, Liu Y, Martin BK, Burkett S, Southon E, Pati D, Tessarollo L, West SC, Donovan PJ, Nussenzweig A, Sharan SK.

J Cell Biol. 2007 Feb 26;176(5):581-92. Epub 2007 Feb 20.


Expression of mutated mouse myocilin induces open-angle glaucoma in transgenic mice.

Senatorov V, Malyukova I, Fariss R, Wawrousek EF, Swaminathan S, Sharan SK, Tomarev S.

J Neurosci. 2006 Nov 15;26(46):11903-14.


BAC rescue: a tool for functional analysis of the mouse genome.

Swing DA, Sharan SK.

Methods Mol Biol. 2004;256:183-98. No abstract available.


Bacterial artificial chromosome engineering.

Swaminathan S, Sharan SK.

Methods Mol Biol. 2004;256:89-106. No abstract available.


BRCA2 deficiency in mice leads to meiotic impairment and infertility.

Sharan SK, Pyle A, Coppola V, Babus J, Swaminathan S, Benedict J, Swing D, Martin BK, Tessarollo L, Evans JP, Flaws JA, Handel MA.

Development. 2004 Jan;131(1):131-42. Epub 2003 Dec 3.


Mini-lambda: a tractable system for chromosome and BAC engineering.

Court DL, Swaminathan S, Yu D, Wilson H, Baker T, Bubunenko M, Sawitzke J, Sharan SK.

Gene. 2003 Oct 2;315:63-9.


Aberrant splicing induced by missense mutations in BRCA1: clues from a humanized mouse model.

Yang Y, Swaminathan S, Martin BK, Sharan SK.

Hum Mol Genet. 2003 Sep 1;12(17):2121-31. Epub 2003 Jul 8.


Brca2 (XRCC11) deficiency results in radioresistant DNA synthesis and a higher frequency of spontaneous deletions.

Kraakman-van der Zwet M, Overkamp WJ, van Lange RE, Essers J, van Duijn-Goedhart A, Wiggers I, Swaminathan S, van Buul PP, Errami A, Tan RT, Jaspers NG, Sharan SK, Kanaar R, Zdzienicka MZ.

Mol Cell Biol. 2002 Jan;22(2):669-79.


Sequence, chromosomal location and expression analysis of the murine homologue of human RAD51L2/RAD51C.

Leasure CS, Chandler J, Gilbert DJ, Householder DB, Stephens R, Copeland NG, Jenkins NA, Sharan SK.

Gene. 2001 Jun 13;271(1):59-67.


Supplemental Content

Loading ...
Support Center